Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach

Health Economics, Policy and Law

Volumn 6, Issue 3, 2011, Pages 391-403

  Antonanzas, Fernando ^a   Juarez Castello, Carmelo ^a   Rodriguez Ibeas, Roberto ^a  

^a UNIVERSITY OF LA RIOJA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTRACT; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; HEALTH CARE COST; HEALTH CARE PERSONNEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REIMBURSEMENT; RISK MANAGEMENT; UNCERTAINTY;

CONTRACTS; DRUG INDUSTRY; HEALTH CARE COSTS; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MODELS, THEORETICAL; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; RISK SHARING, FINANCIAL;

EID: 79960111875     PISSN: 17441331     EISSN: 1744134X     Source Type: Journal    
DOI: 10.1017/S1744133111000016     Document Type: Article

References (19)

1. Begg, E., A. Sidweel, S. Gradiner, G. Nicholls and R. Scott (2003), The sorry saga of the statins in New Zealand-pharmacopolitics versus patient care, New Zealand Medical Journal, 116(1170): 360.
2. Chapman, S., E. Reeve, G. Rajaratnam and R. Neary (2003), Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care, British Medical Journal, 326: 707-709. (Pubitemid 36390459)
3. Chapman, S., E. Reeve, D. Price, G. Rajaratnam and R. Neary (2004), Outcomes guarantee for lipid-lowering drugs: results from a novel approach to risk sharing in primary care, British Journal of Cardiology, 11: 205-210. (Pubitemid 38812074)
4. Claxton, K., L. Ginelly, M. Sculpher, Z. Philips and S. Palmer (2004), A pilot study and the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment Programme, Health Technology Assessment, 8(31): 1-115.
5. Department of Health. (2002), Government of United Kingdom. Cost Effective Provision of Disease Modifying Therapies for People with Multiple Sclerosis. Health Service Circular, no. HSC 2002/004, 4 February 2002; Reviewed on 04 February 2005.
6. Duerden, M., N. Gogna, B. Godman, K. Eden, M. Mallison and N. Sullivan (2004), Current national initiatives and policies to control drug costs in Europe: UK perspective, Journal of Ambulatory Care Management, 27: 132-138. (Pubitemid 38365352)
7. Fenwick, E., K. Claxton and M. Sculpher (2008), The value of implementation and the value of information: combined and uneven development, Medical Decision Making, 28(1): 21-32.
8. Lilico, A. (2003), Risk-sharing Pricing Models in the Distribution of Pharmaceuticals, Staff Working Paper, January 2003, Europe Economics, London.
9. Lu, C. Y., K. Williams, R. Day, L. March, L. Sansom and J. Bertouch (2004), Access to high cost drugs in Australia, British Medical Journal, 329: 415-416. (Pubitemid 39141470)
10. Mzarek, M. (2002), Risk-sharing scheme for the provision of MS drugs, Hospital Pharmacy Europe, 2002: 40-44.
11. Oliva, J., F. Antoñanzas and O. Rivero-Arias (2008), Evaluación econó mica y toma de decisiones en salud. El papel de la evaluación econó mica en la adopción y la difusión de tecnologías sanitarias, Gaceta Sanitaria, 22, Supplement 1: S137-S142.
12. Pita Barros, P. (2007), The Simple Economics of Risk-Sharing Agreements between NHS and The Pharmaceutical Industry, MPRA Paper no. 8517, University Library of Munich, Germany (forthcoming in Health Economics).
13. Pouvourville, G. de. (2006), Risk-sharing agreements for innovative drugs, European Journal of Health Economics, 7: 155-157.
14. Puig-Junoy, J. and R. Meneu (2005), Aplicación de los contratos de riesgo compartido a la financiación de nuevos medicamentos, Gestión Cĺnica y Sanitaria, 7(3): 88-94.
15. Stafinski, T., C. J. McCabe and D. Menon (2010), Funding the unfundable, Pharmacoeconomics, 28(2): 113-142.
16. Sudlow, C. L. M. and C. E. Counsell (2003), Problems with UK governments risk sharing scheme for assessing drugs for multiple sclerosis, British Medical Journal, 326: 388-392. (Pubitemid 36241480)
17. Towse, A. and L. P. Garrison (2010), Cant get no satisfaction? Will pay for performance health?, Pharmacoeconomics, 28(2): 93-102.
18. Yokota, F. and K. M. Thompson (2004), Value of information literature analysis: a review of applications in health risk management, Medical Decision Making, 24(3): 287-298. (Pubitemid 38656313)
19. Zaric, G. S. and B. J. OBrien (2005), Analysis of a pharmaceutical risk sharing agreement based on the purchasers total budget, Health Economics, 14: 793-803. (Pubitemid 41093976)